Antineoplastic Carboplatin CAS 41575-94-4 Raw Materials Powder

CAS: 41575-94-4

MF: C6H12N2O4Pt

Specification​: 99% min Carboplatin Powder

Sample: Carboplatin Powder

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

MADE IN CHINA Store:https://henrikang.en.made-in-china.com/

Carboplatin Powder Usage and Synthesis .

Carboplatin is a second-generation platinum antitumor agent with anticancer activity similar to that of cisplatin, but its nephrotoxicity, ototoxicity, neurotoxicity, and especially gastrointestinal reactions are significantly lower than those of cisplatin, and its antitumor spectrum is not as broad as that of cisplatin. Its mechanism of action is mainly to cause DNA inter-strand and intra-strand cross-linking, interfere with DNA molecules and inhibit cellular DNA synthesis, mainly acting on the N-7 and O-6 atoms of guanine of DNA, producing cytotoxic effects.

Carboplatin Powder is a chemical drug belonging to platinum compounds. Carboplatin Raw Materials are used to treat a variety of malignant tumors, such as ovarian cancer, lung cancer, head and neck cancer, etc. It binds to DNA and interferes with DNA replication and cell division, thus inhibiting the growth and spread of tumor cells. Carboplatin CAS 41575-94-4 is usually administered intravenously, and side effects include nausea, vomiting, and myelosuppression.

Because the cyclobutane ring in the carboplatin molecule is more stable as a ligand than the chloride group in cisplatin, it was initially thought that carboplatin might not be as ototoxic, nephrotoxic, or neurotoxic as cisplatin, but this was demonstrated by systems biology assessment and numerous clinical trials.

The nephrotoxic and myelosuppressive effects as well as the ototoxic and neurotoxic side effects of carboplatin are not as severe as those of cisplatin, but the damage to the body should not be ignored. There is cross-resistance between the antitumor effect of carboplatin and cisplatin in vivo, so tumor cells that are not sensitive to cisplatin are also resistant to carboplatin.

Application/Function of Carboplatin Powder.

Replacement of the carboxyl ligand of carboplatin with a water molecule occurs more slowly than hydration of the chloride ligand of cisplatin. As a result of these reactions, each drug produces active crosslinks, and the differences in their pharmacokinetics indicate their relative potential.

The dose of carboplatin was 4-fold greater than that of cisplatin when applied as a single drug. DNA cross-linking occurs more slowly in cells after carboplatin application than after cisplatin application. Carboplatin is cell cycle non-specific.

In patients with normal renal function, plasma declines about 30 minutes after intravenous administration, and the curve is biphasic in distribution. The half-life is 1 to 2 hours and the terminal half-life is 2.6 to 5.9 hours. The highest tissue concentrations are in the liver, kidney, skin and tumor, suggesting that carboplatin has a similar distribution to cisplatin. Unlike cisplatin, only a very small amount of plasma proteins bind carboplatin.

Second generation platinum complex antitumor agent. The antitumor spectrum and antitumor activity are similar to cisplatin, but the water solubility is better than cisplatin and the toxicity to the kidney is lower. It has better efficacy in small cell lung cancer, ovarian cancer, head and neck squamous carcinoma, testicular tumor, malignant lymphoma, etc. In addition, it can also be used in cervical cancer and bladder cancer. It is a second-generation platinum anticancer drug, whose effects and uses are basically the same as those of cisplatin.

It is more active than cisplatin in some tumors and stronger than cisplatin as a radiosensitizer under hypoxic conditions. It is mainly used in ovarian cancer, testicular cancer, small cell lung cancer and head and neck cancer.

Elimination of the drug is mainly by renal excretion, but without the tubular secretion seen in cisplatin. This may account for the reduced incidence of nephrotoxicity with carboplatin. Sixty-five percent of the drug is excreted in the first 12 hours, 6% in the next 12 hours, and only 3-5% at 96 hours. It is not clear whether the remainder is excreted via bile or other routes. All of the platinum in the 24-hour urine is unchanged carboplatin, suggesting that very little, if any, metabolism occurs. In patients with low creatinine clearance the half-life is longer and the dose should be adjusted accordingly.

Production method of Carboplatin Powder .

The range of action of carboplatin is generally similar to that of cisplatin. The main advantage of this new analogue is the difference in its toxicity profile. Currently, carboplatin is used as palliative treatment for recurrent ovarian cancer, including patients who have previously been treated with cisplatin.

Clinical studies also indicate that carboplatin produces an objective response in head and neck tumors, small cell lung cancer and seminomatous cell tumors of the testis. Carboplatin is currently used clinically for the treatment of small cell lung cancer, ovarian cancer, testicular cancer, germ cell tumors, thyroid cancer, and nasopharyngeal cancer, but also for cervical cancer, non-small cell lung cancer, esophageal cancer, seminoma, bladder cancer, mesothelioma, pediatric brain tumors, and other head and neck cancers and other malignancies.

It is available for patients who cannot tolerate cisplatin due to renal impairment, intractable vomiting, hearing loss or neurotoxicity. It has no cross-resistance with other chemotherapeutic agents and can be used alone or in combination with other chemical drugs, and can be used in combination with surgery and radiotherapy to improve the therapeutic effect.